Keywords: UK, AstraZeneca, NICE, Iressa, Lung cancer,
NICE requests more data on AstraZeneca’s Iressa for NSC lung cancer, notably on cost effectiveness
Article | 29 January 2010
In draft guidance published today, the UK’s National Institute for Health and Clinical Excellence (NICE) has asked Anglo-Swedish drug major AstraZeneca to provide more data on the effectiveness of its product Iressa (gefitinib, as a treatment for locally-advanced or metastatic non small cell lung cancer.
This draft guidance has been issued for consultation and AstraZeneca now has an opportunity to respond to the independent Appraisal Committee’s considerations and requests. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
